Surgical treatment and prognosis of pancreatic neuroendocrine carcinoma
10.3760/cma.j.issn.0253-3766.2016.12.009
- VernacularTitle:胰腺神经内分泌癌的外科治疗和预后
- Author:
Jianwei ZHANG
1
;
Xu CHE
;
Zhongmin LAN
;
Yingtai CHEN
;
Xianghui HUANG
;
Qinglong JIANG
;
Chengfeng WANG
Author Information
1. 100021国家癌症中心,中国医学科学院北京协和医学院肿瘤医院腹部外科
- Keywords:
Subject words] Pancreatic neoplasms;
Neuroendocrine carcinomas;
Therapy;
Surgery;
Prognosis
- From:
Chinese Journal of Oncology
2016;38(12):925-928
- CountryChina
- Language:Chinese
-
Abstract:
Objective Pancreatic neuroendocrine carcinoma ( pNEC) is a highly malignant tumor. This study aimed to evaluate the role of surgery and the prognosis for patients with pancreatic neuroendocrine carcinoma ( pNEC ) . Methods We collected and reviewed all clinical data of patients who underwent radical surgery for pNEC from Jan 2000 through Jan 2016 in our hospital. Cox?regression analysis wasused to evaluate the factors potentially influencing survival. Results Twenty patients including 11 males and 9 females ( median age, 62.5 years) were included in this study. All patients underwent radical surgery and 17 cases received postoperative platinum?based chemotherapy. The median follow?up time was 41 months (range, 1 to 127 months).The 1?,3?, and 5?year survival rates of the patients were 66.7%, 51.5% and 28.1%, with a median survival time of 75.3 months.The multivariate analysis indicated that tumor size and Ki?67 index were of prognostic significance. Conclusions Pancreatic neuroendocrine carcinomas are rare but increasing in incidence. Patients with localized nonmetastatic primary tumors seem to benefit from surgery. Early diagnosis and multimodality therapy are key points of an improved survival.
